Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant...

Area of Science:

• Infectious Diseases
• Pharmacology
• Microbiology

Background:

• Tedizolid is a novel oxazolidinone antibiotic with in vitro activity against Staphylococcus aureus.
• Oxazolidinones are important in treating infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

Purpose of the Study:

• To evaluate the in vivo efficacy of tedizolid phosphate against MRSA aortic valve endocarditis (AVE) in a rabbit model.
• To compare tedizolid phosphate with vancomycin and daptomycin, and to determine the minimum effective dose of tedizolid phosphate.

Main Methods:

• A rabbit model of aortic valve endocarditis was established using methicillin-resistant Staphylococcus aureus (MRSA).
• Rabbits were treated with tedizolid phosphate (15 mg/kg twice daily), vancomycin (30 mg/kg twice daily), or daptomycin (18 mg/kg once daily).
• A dose-ranging study of tedizolid phosphate (2, 4, 8 mg/kg twice daily) compared to vancomycin was also conducted.

Main Results:

• Daptomycin demonstrated significantly lower median vegetation titers than tedizolid phosphate (15 mg/kg).
• No significant difference in vegetation titers was observed between vancomycin and tedizolid phosphate (15 mg/kg).
• Tedizolid phosphate at 4 mg/kg and 8 mg/kg showed reduced vegetation titers but were less efficacious than vancomycin; 2 mg/kg was not efficacious.

Conclusions:

• Tedizolid phosphate at 15 mg/kg was less efficacious than daptomycin and comparable to vancomycin for MRSA AVE in rabbits.
• Lower doses of tedizolid phosphate were not as effective as vancomycin, suggesting potential limitations in efficacy for this indication.
• Further investigation is required to establish optimal dosing and therapeutic potential of tedizolid phosphate in complex infections.